Polyclonal and Anti-PD1 Antibody Combination for Cold Tumors

The invention segments the antibody population into two distinct functional groups: polyclonal antibodies (pAbs) that provide broad epitope coverage and monoclonal antibodies (mAbs) that provide specific checkpoint blocking. This segmentation allows each component to perform its specialized function without the harmful effects of using pAbs alone - the mAbs component specifically blocks PD-1/PD-L1 interactions without causing cross-reactivity toxicity, while the pAbs component provides broad coverage without requiring high doses that would cause toxicity.

The invention introduces monoclonal anti-PD-1/PD-L1 antibodies as an intermediary substance that mediates the interaction between the polyclonal antibody mixture and the tumor. The mAbs act as a selective filter that enhances the anti-tumor effect of the pAbs by specifically blocking immune checkpoint pathways, while the combination formulation ensures that the pAbs are not diluted or rendered ineffective by the mAbs, maintaining both efficacy and reduced toxicity.

The invention divides the antibody therapy into two segments: monoclonal antibodies for specific checkpoint blocking and polyclonal antibodies for broad epitope coverage. The mAbs segment provides precise targeting of PD-1/PD-L1 interactions, while the pAbs segment compensates for resistance mechanisms by targeting multiple different epitopes on tumor cells simultaneously, preventing immunoselection and immunosubversion that would occur with mAbs alone.

The invention creates a composite antibody formulation combining both monoclonal and polyclonal antibodies. This composite approach leverages the advantages of both types: the mAbs provide specific checkpoint inhibition with high precision, while the pAbs provide broad spectral coverage that prevents tumor escape mechanisms. The synergistic combination achieves both specificity and reliability that neither component could achieve alone.

The monoclonal anti-PD-1/PD-L1 antibodies serve as an intermediary that enhances the effectiveness of the polyclonal antibodies at lower doses. By blocking immune checkpoint pathways, the mAbs create a more favorable immunological environment that amplifies the anti-tumor effect of the pAbs, reducing the dose required and thereby minimizing toxicity while maintaining adequate tumor coverage.

The composite formulation of mAbs and pAbs allows the pAbs to be administered at lower, more tolerable doses because the mAbs component provides a significant portion of the anti-tumor effect through specific checkpoint blocking. This composite approach eliminates the need to administer high doses of pAbs alone to achieve sufficient tumor coverage, thereby reducing toxicity while maintaining reliability.